Tonix Pharmaceuticals stock halted ahead of FDA approval news
Investing.com - H.C. Wainwright reduced its price target on Humacyte (NASDAQ:HUMA) to $3.00 from $4.00 on Tuesday, while maintaining a Buy rating following the company’s second-quarter financial results. The biotech company, currently trading at $1.75 with a market capitalization of $271 million, has seen its stock decline 74% over the past year.
The biotech firm reported $301,000 in revenue for the second quarter of 2025, with $100,000 coming from Symvess product sales and $201,000 from a research collaboration with an unnamed medical technology company. According to InvestingPro data, the company maintains strong liquidity with a current ratio of 3.68, though it’s currently operating with negative profit margins.
Despite weak first-half performance, Humacyte saw improved Symvess adoption in July, generating $300,000 in sales for the month alone, exceeding the entire first-half sales of $247,000.
H.C. Wainwright noted several factors that could improve commercial momentum in the second half of 2025, including a price reduction for Symvess to $24,250 from $29,500, increased hospital eligibility for purchases, and inclusion in the U.S. Defense Logistics Agency’s Electronic Catalog.
The research firm lowered its 2025 total revenue forecast to $2.5 million from $10.4 million and reduced its 2026 revenue projection to $15.3 million from $32.9 million, citing weak first-half sales despite acknowledging growth potential.
In other recent news, Humacyte reported its second-quarter 2025 earnings, revealing a notable shortfall in both earnings and revenue. The company posted an earnings per share (EPS) of -$0.24, which fell short of the forecasted -$0.16. Additionally, Humacyte’s revenue was reported at $301,000, significantly missing the expected $1.01 million. Following these results, BTIG adjusted its price target for Humacyte, lowering it to $7.00 from a previous target of $8.00, though the firm maintained its Buy rating. These developments indicate a larger-than-expected loss for the quarter, as the company struggled to meet both its own and analysts’ projections. Investors are advised to consider these recent developments as they assess Humacyte’s financial performance and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.